{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:53:32Z","timestamp":1792752812392,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11154-021-09694-6","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:17:50Z","timestamp":1642479470000},"page":"485-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8443","authenticated-orcid":false,"given":"Manju","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Rajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha Peiling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miny","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"6","key":"9694_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.beem.2018.12.001","volume":"32","author":"RJ Egan","year":"2018","unstructured":"Egan RJ, Scott-Coombes DM. The surgical management of sporadic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):847\u201359. https:\/\/doi.org\/10.1016\/j.beem.2018.12.001.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"9694_CR2","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00268-016-3514-1","volume":"40","author":"NM Singh Ospina","year":"2016","unstructured":"Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S, et al. Outcomes of parathyroidectomy in patients with primary hyperparathyroidism: A systematic review and meta-analysis. World J Surg. 2016;40(10):2359\u201377. https:\/\/doi.org\/10.1007\/s00268-016-3514-1.","journal-title":"World J Surg"},{"issue":"1","key":"9694_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/10408360590886606","volume":"42","author":"J Tfelt-Hansen","year":"2005","unstructured":"Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: A review. Crit Rev Clin Lab Sci. 2005;42(1):35\u201370. https:\/\/doi.org\/10.1080\/10408360590886606.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9694_CR4","doi-asserted-by":"publisher","unstructured":"Verheyen N, Pilz S, Eller K, et al. Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opin Pharmacother. 2013;14(6):793\u2013806. https:\/\/doi.org\/10.1517\/14656566.2013.777041.","DOI":"10.1517\/14656566.2013.777041."},{"issue":"7","key":"9694_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1530\/EC-20-0221","volume":"9","author":"CH Ng","year":"2020","unstructured":"Ng CH, Chin YH, Tan MHQ, et al. Cinacalcet and primary hyperparathyroidism: Systematic review and meta regression. Endocr Connect. 2020;9(7):724\u201335. https:\/\/doi.org\/10.1530\/EC-20-0221.","journal-title":"Endocr Connect"},{"key":"9694_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2632","volume":"370","author":"J-P Salameh","year":"2020","unstructured":"Salameh J-P, Bossuyt PM, McGrath TA, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist. BMJ. 2020;370: m2632. https:\/\/doi.org\/10.1136\/bmj.m2632.","journal-title":"BMJ"},{"key":"9694_CR7","doi-asserted-by":"publisher","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. Jama. 2000;283(15):2008\u201312. https:\/\/doi.org\/10.1001\/jama.283.15.2008.","DOI":"10.1001\/jama.283.15.2008."},{"key":"9694_CR8","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919\u2013i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"5","key":"9694_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1530\/EJE-14-0877","volume":"172","author":"A Khan","year":"2015","unstructured":"Khan A, Bilezikian J, Bone H, et al. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol. 2015;172(5):527\u201335. https:\/\/doi.org\/10.1530\/EJE-14-0877.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"9694_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(1):135\u201341. https:\/\/doi.org\/10.1210\/jc.2004-0842.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9694_CR11","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"DM Shoback","year":"2003","unstructured":"Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(12):5644\u20139. https:\/\/doi.org\/10.1210\/jc.2002-021597.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9694_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1530\/EJE-12-0117","volume":"167","author":"M Filopanti","year":"2012","unstructured":"Filopanti M, Verga U, Ermetici F, et al. MEN1-related hyperparathyroidism: Response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol. 2012;167(2):157\u201364. https:\/\/doi.org\/10.1530\/EJE-12-0117.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"9694_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s2213-8587(20)30063-2","volume":"8","author":"JS Leere","year":"2020","unstructured":"Leere JS, Karmisholt J, Robaczyk M, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8(5):407\u201317. https:\/\/doi.org\/10.1016\/s2213-8587(20)30063-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"9694_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4103\/ijem.IJEM_684_17","volume":"22","author":"H Abusahmin","year":"2018","unstructured":"Abusahmin H, Surya A, Aldridge A, Okosieme O, Das G. Cinacalcet: a viable therapeutic option for primary hyperparathyroidism in the elderly. Indian J Endocrinol Metab Jul-Aug. 2018;22(4):485\u20138. https:\/\/doi.org\/10.4103\/ijem.IJEM_684_17.","journal-title":"Indian J Endocrinol Metab Jul-Aug"},{"issue":"3","key":"9694_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5603\/ep.2017.0023","volume":"68","author":"W Misiorowski","year":"2017","unstructured":"Misiorowski W, Zgliczy\u0144ski W. Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgery. Endokrynol Pol. 2017;68(3):306\u201310. https:\/\/doi.org\/10.5603\/ep.2017.0023.","journal-title":"Endokrynol Pol"},{"issue":"3","key":"9694_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","volume":"52","author":"F Giusti","year":"2016","unstructured":"Giusti F, Cianferotti L, Gronchi G, et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine. 2016;52(3):495\u2013506. https:\/\/doi.org\/10.1007\/s12020-015-0696-5.","journal-title":"Endocrine"},{"issue":"1","key":"9694_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","volume":"87","author":"S Brardi","year":"2015","unstructured":"Brardi S, Cevenini G, Verdacchi T, Romano G, Ponchietti R. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch Ital Urol Androl. 2015;87(1):66\u201371. https:\/\/doi.org\/10.4081\/aiua.2015.1.66.","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"9694_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12020-014-0381-0","volume":"49","author":"V Marotta","year":"2015","unstructured":"Marotta V, Di Somma C, Rubino M, et al. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. Endocrine. 2015;49(1):274\u20138. https:\/\/doi.org\/10.1007\/s12020-014-0381-0.","journal-title":"Endocrine"},{"issue":"6","key":"9694_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1530\/EJE-14-0355","volume":"171","author":"P Schwarz","year":"2014","unstructured":"Schwarz P, Body JJ, Cap J, et al. The PRIMARA study: A prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol. 2014;171(6):727\u201335. https:\/\/doi.org\/10.1530\/EJE-14-0355.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"9694_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2042018813482344","volume":"4","author":"I Luque-Fern\u00e1ndez","year":"2013","unstructured":"Luque-Fern\u00e1ndez I, Garc\u00eda-Mart\u00edn A, Luque-Pazos A. Experience with cinacalcet in primary hyperparathyroidism: Results after 1 year of treatment. Ther Adv Endocrinol Metab. 2013;4(3):77\u201381. https:\/\/doi.org\/10.1177\/2042018813482344.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"9694_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cen.12108","volume":"79","author":"F Saponaro","year":"2013","unstructured":"Saponaro F, Faggiano A, Grimaldi F, et al. Cinacalcet in the management of primary hyperparathyroidism: Post marketing experience of an Italian multicentre group. Clin Endocrinol (Oxf). 2013;79(1):20\u20136. https:\/\/doi.org\/10.1111\/cen.12108.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"9694_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3275\/7970","volume":"35","author":"F Cetani","year":"2012","unstructured":"Cetani F, Saponaro F, Banti C, et al. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest. 2012;35(7):655\u201360. https:\/\/doi.org\/10.3275\/7970.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"9694_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/SLA.0b013e31824c5252","volume":"255","author":"XM Keutgen","year":"2012","unstructured":"Keutgen XM, Buitrago D, Filicori F, et al. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: Retrospective chart analysis of a prospective database. Ann Surg. 2012;255(5):981\u20135. https:\/\/doi.org\/10.1097\/SLA.0b013e31824c5252.","journal-title":"Ann Surg"},{"issue":"5","key":"9694_CR24","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1245\/s10434-011-2065-9","volume":"19","author":"J Norman","year":"2012","unstructured":"Norman J, Lopez J, Politz D. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use. Ann Surg Oncol. 2012;19(5):1466\u201371. https:\/\/doi.org\/10.1245\/s10434-011-2065-9.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"9694_CR25","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1210\/jc.2008-2640","volume":"94","author":"C Marcocci","year":"2009","unstructured":"Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(8):2766\u201372. https:\/\/doi.org\/10.1210\/jc.2008-2640.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"9694_CR26","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1210\/jc.2009-1472","volume":"94","author":"M Peacock","year":"2009","unstructured":"Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94(12):4860\u20137. https:\/\/doi.org\/10.1210\/jc.2009-1472.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9694_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","volume":"57","author":"S Sajid-Crockett","year":"2008","unstructured":"Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57(4):517\u201321. https:\/\/doi.org\/10.1016\/j.metabol.2007.11.014.","journal-title":"Metabolism"},{"issue":"8","key":"9694_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1507\/endocrj.EJ19-0034","volume":"66","author":"K Manaka","year":"2019","unstructured":"Manaka K, Sato J, Kinoshita Y, et al. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: A single center experience. Endocr J. 2019;66(8):683\u20139. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0034.","journal-title":"Endocr J"},{"key":"9694_CR29","doi-asserted-by":"publisher","unstructured":"Duskin-Bitan H, Nemirovsky N, Slutzky-Shraga I, et al. Hyperparathyroidism in patients over 75: Clinical characteristics and outcome. Is conservative treatment a safe alternative? Maturitas. 2020;135:47\u201352. https:\/\/doi.org\/10.1016\/j.maturitas.2020.02.010.","DOI":"10.1016\/j.maturitas.2020.02.010."},{"issue":"13","key":"9694_CR30","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/bjs.11319","volume":"106","author":"A Koman","year":"2019","unstructured":"Koman A, Ohlsson S, Br\u00e4nstr\u00f6m R, Pernow Y, Br\u00e4nstr\u00f6m R, Nilsson IL. Short-term medical treatment of hypercalcaemia in primary hyperparathyroidism predicts symptomatic response after parathyroidectomy. Br J Surg. 2019;106(13):1810\u20138. https:\/\/doi.org\/10.1002\/bjs.11319.","journal-title":"Br J Surg"},{"key":"9694_CR31","first-page":"N87","volume":"17","author":"M Peacock","year":"2002","unstructured":"Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. 2002;17:N87-94.","journal-title":"Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research"},{"issue":"5","key":"9694_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/01.tp.0000232452.80018.ad","volume":"82","author":"I Szwarc","year":"2006","unstructured":"Szwarc I, Argil\u00e9s A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation. 2006;82(5):675\u201380. https:\/\/doi.org\/10.1097\/01.tp.0000232452.80018.ad.","journal-title":"Transplantation"},{"key":"9694_CR33","doi-asserted-by":"publisher","unstructured":"Borchhardt KA, Heinzl H, Mayerwoger E, H\u00f6rl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation. 2008;86(7):919\u201324. https:\/\/doi.org\/10.1097\/TP.0b013e318186b7fb","DOI":"10.1097\/TP.0b013e318186b7fb"},{"issue":"5","key":"9694_CR34","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/j.1523-1755.2005.00302.x","volume":"67","author":"G Vezzoli","year":"2005","unstructured":"Vezzoli G, Soldati L, Arcidiacono T, et al. Urinary calcium is a determinant of bone mineral density in elderly men participating in the InCHIANTI study. Kidney Int. 2005;67(5):2006\u201314. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00302.x.","journal-title":"Kidney Int"},{"issue":"1","key":"9694_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.surg.2020.06.012","volume":"169","author":"C McManus","year":"2021","unstructured":"McManus C, Oh A, Lee JA, Hur C, Kuo JH. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis. Surgery. 2021;169(1):94\u2013101. https:\/\/doi.org\/10.1016\/j.surg.2020.06.012.","journal-title":"Surgery"},{"issue":"2","key":"9694_CR36","doi-asserted-by":"publisher","first-page":"c151","DOI":"10.1159\/000319781","volume":"117","author":"GT Schumock","year":"2011","unstructured":"Schumock GT, Walton SM, Lee TA, Marx SE, Audhya P, Andress DL. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin Pract. 2011;117(2):c151\u20139. https:\/\/doi.org\/10.1159\/000319781.","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"9694_CR37","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483\u201390. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00878.x.","journal-title":"Kidney Int"},{"key":"9694_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.712027","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Cai L, Wu H, et al. Paricalcitol versus calcitriol + cinacalcet for the treatment of secondary hyperparathyroidism in chronic kidney disease in China: A cost-effectiveness analysis. Front Public Health. 2021;9: 712027. https:\/\/doi.org\/10.3389\/fpubh.2021.712027.","journal-title":"Front Public Health"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-021-09694-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T02:27:04Z","timestamp":1653964024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-021-09694-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["9694"],"URL":"https:\/\/doi.org\/10.1007\/s11154-021-09694-6","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"2 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}